Literature DB >> 3136116

The mechanism of acquired resistance to cisplatin by a human ovarian cancer cell line.

Y Kikuchi1, I Iwano, M Miyauchi, T Kita, K Oomori, I Kizawa, M Sugita, Y Tenjin.   

Abstract

The present study was designed to elucidate the mechanism of resistance to cisplatin. A cisplatin-resistant cell line (KFr) was established from KF cells derived from human serous cystadenocarcinoma of the ovary. The DNA histogram revealed an increase of S-phase cells and a decrease of G1-phase cells in cultured KFr cells, compared to that in cultured KF cells. Although the cisplatin content in the KF cells incubated with cisplatin at 10 micrograms/ml increased in a time-dependent manner, that in the KFr cells remained unchanged during the experimental period. When 0.5 mg of cisplatin was administered ip to nude mice with KF or KFr tumor, the cisplatin content in the KFr tumor was significantly lower than that in the KF tumor. The KFr cells showed a cross-resistance to L-phenylalanine mustard, while no cross-resistance to vincristine or 5-fluorouracil was observed. These findings suggest that the mechanism of cisplatin resistance in the KFr cells involves a decrease of cisplatin accumulation in the tumor cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3136116      PMCID: PMC5917564          DOI: 10.1111/j.1349-7006.1988.tb00033.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


L‐phenylalanine mustard 5‐fluorouracil
  15 in total

1.  Establishment of a cisplatin-resistant human ovarian cancer cell line.

Authors:  Y Kikuchi; M Miyauchi; I Kizawa; K Oomori; K Kato
Journal:  J Natl Cancer Inst       Date:  1986-12       Impact factor: 13.506

Review 2.  Fundamental studies with cisplatin.

Authors:  B Rosenberg
Journal:  Cancer       Date:  1985-05-15       Impact factor: 6.860

Review 3.  Chemotherapy of ovarian cancer.

Authors:  R F Ozols; R C Young
Journal:  Semin Oncol       Date:  1984-09       Impact factor: 4.929

4.  Carrier-dependent and carrier-independent transport of anti-cancer alkylating agents.

Authors:  J E Byfield; P M Calabro-Jones
Journal:  Nature       Date:  1981-11-19       Impact factor: 49.962

5.  Current therapy of ovarian carcinoma: an overview.

Authors:  T Thigpen; J A Blessing
Journal:  Semin Oncol       Date:  1985-09       Impact factor: 4.929

6.  Pharmacologic reversal of drug resistance in ovarian cancer.

Authors:  R F Ozols
Journal:  Semin Oncol       Date:  1985-09       Impact factor: 4.929

Review 7.  Drugs five years later. Cisplatin.

Authors:  P J Loehrer; L H Einhorn
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

8.  Effects of amino acids on the transport and cytotoxicity of melphalan by human bone marrow cells and human tumor cells.

Authors:  M Dufour; L C Panasci; J St Germain; L Boulet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

Authors:  F M Schabel; M W Trader; W R Laster; T H Corbett; D P Griswold
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

10.  Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining.

Authors:  A Krishan
Journal:  J Cell Biol       Date:  1975-07       Impact factor: 10.539

View more
  3 in total

1.  Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.

Authors:  M Takakura; M Nakamura; S Kyo; M Hashimoto; N Mori; T Ikoma; Y Mizumoto; T Fujiwara; Y Urata; M Inoue
Journal:  Cancer Gene Ther       Date:  2010-01       Impact factor: 5.987

2.  Integrative microRNA and gene expression analysis identifies new epigenetically regulated microRNAs mediating taxane resistance in ovarian cancer.

Authors:  Mohamed K Hassan; Amr A Waly; Waheba Elsayed; Sarah Keshk; Walaa Ramadan Allam; Sherif F El-Khamisy
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

3.  Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; T Morikage; Y Fujiwara; N Saijo
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.